Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday.

According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “

Other analysts have also issued research reports about the stock. Canaccord Genuity set a $20.00 target price on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Saturday, August 6th. HC Wainwright reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Tuesday, November 8th. Jefferies Group reiterated a “buy” rating and issued a $12.00 target price on shares of Karyopharm Therapeutics in a research note on Tuesday, November 8th. Wedbush reiterated an “outperform” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a research note on Tuesday, November 8th. Finally, Robert W. Baird reiterated a “positive” rating and issued a $16.00 target price on shares of Karyopharm Therapeutics in a research note on Tuesday, September 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Karyopharm Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $15.47.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI) opened at 9.87 on Thursday. Karyopharm Therapeutics has a 52-week low of $4.83 and a 52-week high of $19.41. The company’s market capitalization is $407.07 million. The company’s 50-day moving average is $8.75 and its 200-day moving average is $8.29.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Monday, November 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.12. On average, analysts expect that Karyopharm Therapeutics will post ($3.00) earnings per share for the current fiscal year.

In other news, insider Ran Frenkel sold 3,309 shares of the stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $10.06, for a total value of $33,288.54. Following the sale, the insider now directly owns 14,691 shares of the company’s stock, valued at $147,791.46. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 14.79% of the company’s stock.

Several large investors have recently made changes to their positions in KPTI. Rhumbline Advisers increased its stake in shares of Karyopharm Therapeutics by 188.5% in the second quarter. Rhumbline Advisers now owns 64,460 shares of the company’s stock worth $433,000 after buying an additional 42,119 shares during the last quarter. TFS Capital LLC purchased a new stake in shares of Karyopharm Therapeutics during the second quarter worth about $335,000. Alliancebernstein L.P. increased its stake in shares of Karyopharm Therapeutics by 24.2% in the second quarter. Alliancebernstein L.P. now owns 34,930 shares of the company’s stock worth $234,000 after buying an additional 6,800 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in shares of Karyopharm Therapeutics by 3.2% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 530,816 shares of the company’s stock worth $3,562,000 after buying an additional 16,388 shares during the last quarter. Finally, BlackRock Fund Advisors increased its stake in shares of Karyopharm Therapeutics by 1.1% in the second quarter. BlackRock Fund Advisors now owns 1,069,779 shares of the company’s stock worth $7,178,000 after buying an additional 11,907 shares during the last quarter. 55.99% of the stock is currently owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

5 Day Chart for NASDAQ:KPTI

Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.